ClinicalTrials.gg
CompletedNCT03277313Updated Oct 23, 2023Results posted

Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects

A Phase 3 interventional study of HYQVIA in Primary Immunodeficiency Diseases (PID), sponsored by Baxalta now part of Shire. Completed at 19 sites in United States. Open to participants aged 2 Years to 15 Years. Per ClinicalTrials.gov, last updated 2023-10-23.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
44
Allocation
Non-randomized
Ages
2 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulin G · Primary Immunodeficiency Diseases.

Enrollment
15th of 28
44 · median 45
Started
2017
with 2 others
Phase 3
20 of 29
2 open now
Registered
23rd of 29
by date
Lead sponsor
9 of 29
Baxalta now part of Shire

Among the 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases, this one is the 15th largest by enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2017, is one of 20 in phase 3, and was the 23rd registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:

All 2 open studies →

About Immunoglobulin G

Immunoglobulin G: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing Immunoglobulin G in Primary Immunodeficiency Diseases, or all of them as a file.
02

Study summary

The purpose of the study is to acquire additional data on efficacy, safety, tolerability, immunogenicity, pharmacokinetic (PK) and other parameters of HYQVIA in pediatric (age ≥ 2 to \<16 years) participants with primary immunodeficiency disease (PIDD).

03

Conditions studied

  • Primary Immunodeficiency Diseases (PID)
04

Who can participate

Ages eligible
2 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must have a documented diagnosis of a form of primary immunodeficiency (PI) involving a defect in antibody formation and requiring gammaglobulin replacement, as defined according to the International Union of Immunological Societies (IUIS) Scientific Committee 2015 (Picard et al., 2015) prior to enrollment. The diagnosis must be confirmed by the sponsor´s Medical Director prior to first treatment with IP in the study.
  2. Participant is at least two and below 16 years of age at the time of screening.
  3. Participant has been receiving a consistent dose of Immunoglobulin G (IgG), administered in compliance with the respective product information for a period of at least three months prior to screening. The average minimum pre-study dose over that interval was equivalent to 300 mg/kg BW / 4 weeks and a maximum dose equivalent to 1000 mg/kg body weight (BW) / 4 weeks.
  4. Participant has a serum trough level of IgG > 5 g/L at screening.
  5. If female of , participant presents with a negative pregnancy test and agrees to employ adequate measures for the duration of the study.
  6. Participant /legally authorized representative is willing and able to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Participant has a known history of or is positive at screening for one or more of the following: surface antigen (HBsAg), polymerase chain reaction (PCR) for virus (HCV), PCR for (HIV) Type 1/2.
  2. Abnormal laboratory values at screening meeting any one of the following criteria (abnormal tests may be repeated once to determine if they are persistent):

    1. Persistent (ALT) and aspartate aminotransferase (AST) > 2.5 times the (ULN) for the testing laboratory
    2. Persistent severe neutropenia (defined as an [ANC] ≤ 500/mm\^3)
  3. Participant has anemia that would preclude phlebotomy for laboratory studies, according to standard practice at the site.
  4. Participant has an ongoing history of or persistent reactions (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following intravenous (IV) immunoglobulin, subcutaneous (SC) immunoglobulin, and/or Immune Serum Globulin (ISG) infusions.
  5. Participant has severe Immunoglobulin A (IgA) deficiency (less than 7.0 mg/dL) with known anti-IgA antibodies and a history of hypersensitivity.
  6. Participant has a known allergy to hyaluronidase.
  7. Participant has active infection and is receiving antibiotic therapy for the treatment of infection at the time of screening.
  8. Participant has a bleeding disorder or a count less than 20,000/μL, or who, in the opinion of the investigator, would be at significant risk of increased bleeding or bruising as a result of SC therapy.
  9. Participant has severe dermatitis that would preclude adequate sites for safe product administration in the opinion of the investigator.
  10. Participant has participated in another clinical study involving an IP or device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
  11. Participant is a family member or employee of the investigator.
  12. If female, participant is pregnant or lactating at the time of enrollment.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Epoch 1

    Pediatric participants with PIDD who were on IV or non-HYQVIA SC treatment with immunoglobulin were enrolled and treated with HYQVIA SC with a dose or interval ramp-up period of up to six weeks. HYQVIA dose was planned to be equivalent to 100% (± 5%) of pre-study treatment. Dose frequency was one treatment interval of one week, then one treatment interval of two weeks for participants who were planned to be treated every three weeks, and one more treatment interval of three weeks for participants who were planned to be treated every four weeks.

    Biological: HYQVIA

  • Experimental
    Epoch 2

    Epoch 1 was followed by Epoch 2 with HYQVIA treatment infusions given once every 3 or 4 weeks, depending on the participant's previous IV dosing schedule (for IV pretreated participants) and at the discretion of the investigator and participant (for SC-pretreated participants) up to approximately 36 months.

    Biological: HYQVIA

Interventions

  • BiologicalHYQVIA

    Drug pages: Immunoglobulin G · Hyaluronoglucosaminidase

    Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)

    Also known as: IGI 10% with rHuPH20

06

What researchers measure

Primary outcomes

  1. Rate Represented as Mean Number of Acute Serious Bacterial Infections (ASBI) Per Participant-year

    The rate of ASBI was defined as the mean number of ASBI per participant-year based on the United States (U.S.) Food and drugs Administration (FDA) guidance for industry to support marketing of human immune globulin intravenous (IGIV) as replacement therapy for primary humoral immunodeficiency and the European Medicines Agency (EMA) guideline on the clinical investigation of human normal immunoglobulin for SC and /or intramuscular administration. ASBI included bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess, diagnosed according to the Diagnostic Criteria for Acute Serious Bacterial Infections.

    Time frame: From first dose of study drug up to end of Study Epoch 2 (up to approximately 37.2 months)

Secondary outcomes

  1. Rate Represented as Mean Number of All Infections Per Participant-year

    The rate of all infections was defined as the mean number of all infections per participant-year. Number of all infections was calculated as number of infections per participant-year.

    Time frame: From first dose of study drug up to end of Study Epoch 2 (up to approximately 37.2 months)

  2. Epoch 2: Trough Levels of Immunoglobulin G (IgG) Total and IgG Subclasses

    Time frame: Study Epoch 2, Year 1: Months 0, 6, and 12; Year 2: Months 18, 24 and 36

  3. Epoch 2: Trough Levels of Specific Antibodies to Clinically Relevant Pathogens Categorized as Clostridium Tetani Toxoid and Hepatitis B Virus

    Time frame: Study Epoch 2, Year 2: Months 6, 24, and 36

  4. Epoch 2: Trough Levels of Specific Antibodies to Clinically Relevant Pathogen Haemophilus Influenzae B

    Time frame: Study Epoch 2, Year 2: Months 6, 24, and 36

  5. Epoch 2: Area Under the Curve Normalized for Week (AUCweek)

    Time frame: Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion

  6. Epoch 2: Area Under the Curve Over the Infusion Interval (AUCTau)

    Time frame: Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion

  7. Epoch 2: Apparent Clearance (CL/F)

    Time frame: Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion

  8. Epoch 2: Maximum Concentration (Cmax)

    Time frame: Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion

  9. Epoch 2: Minimum Concentration (Cmin)

    Time frame: Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion

  10. Epoch 2: Time to Maximum Concentration (Tmax)

    Time frame: Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion

  11. Epoch 2: Terminal Half-life (T 1/2)

    Time frame: Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion

  12. Number of Participants With Serious Adverse Events (SAEs) Excluding Infections, Related and Not Related

    An SAE is defined as an untoward medical occurrence that at any dose is fatal, life-threatening, requires inpatient hospitalization or results in prolongation of an existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event. Number of participants who experienced SAEs, related or not related, was reported.

    Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)

  13. Rate of SAEs Excluding Infections, Related and Not Related, Per Infusion

    Rate of SAEs per infusion was calculated as number of serious adverse events/total number of infusions administered to participants in the analysis set. Rate of SAEs per infusion (excluding infections) was reported.

    Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)

  14. Number of Participants With All Treatment Emergent Adverse Events (TEAEs) Excluding Infections, Related and Not Related

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants who experienced TEAEs, related or not related, was reported.

    Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)

  15. Rate of All TEAEs Excluding Infections, Related and Not Related, Per Infusion

    Rate of all TEAEs per infusion was calculated as number of any adverse reaction events/total number of infusions administered to participants in the analysis set. Rate of any adverse reactions per infusion (excluding infections) was reported.

    Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)

  16. Number of Participants With Local TEAEs Excluding Infections, Related and Not Related

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants who experienced local TEAEs, related or not related, was reported.

    Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)

  17. Rate of Local TEAEs Excluding Infections, Related and Not Related, Per Infusion

    Rate of local TEAEs per infusion was calculated as number of local TEAEs/total number of infusions administered to participants in the analysis set. Rate of local TEAEs per infusion (excluding infections) was reported.

    Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)

  18. Number of Participants With Systemic TEAEs Excluding Infections, Related and Not Related

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants who experienced systemic TEAEs, related or not related, was reported.

    Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)

  19. Rate of Systemic TEAEs Excluding Infections, Related and Not Related, Per Infusion

    Rate of systemic TEAEs per infusion was calculated as number of systemic TEAEs/total number of infusions administered to participants in the analysis set. Rate of systemic TEAEs per infusion (excluding infections) was reported.

    Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)

  20. Number of Participants With All Temporally Associated TEAEs Excluding Infections

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants who experienced all temporally associated TEAEs, related or not related, was reported.

    Time frame: From beginning of infusion up to 72 hours post infusion

  21. Rate of All Temporally Associated TEAEs Excluding Infections Per Infusion

    Rate of all temporally associated TEAEs per infusion was calculated as number of all temporally associated TEAEs/total number of infusions administered to participants in the analysis set. Rate of all temporally associated TEAEs per infusion (excluding infections) was reported.

    Time frame: From beginning of infusion up to 72 hours post infusion

  22. Number of Participants With All Related (Causally) and/or Temporally Associated TEAEs Excluding Infections

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants with any related (causally) and/or temporally associated TEAEs (excluding infections) was reported. Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion.

    Time frame: From beginning of infusion up to 72 hours post infusion

  23. Rate of Participants With All Related (Causally) and/or Temporally Associated TEAEs Excluding Infections Per Infusion

    Rate of any related (causally) and/or temporally associated TEAEs per infusion was calculated as number of related and/or temporally associated adverse events/ total number of infusions administered to participants in the analysis set. TEAEs recorded in the study database as "possibly related" or "probably related" to HYQVIA are considered HYQVIA-related adverse events. Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion. Rate of any related (causally) and/or temporally associated TEAEs per infusion (excluding infections) was reported.

    Time frame: From beginning of infusion up to 72 hours post infusion

  24. Percentage of Participants With Any TEAEs Excluding Infections

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Percentages are rounded off to whole number at the nearest decimal.

    Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)

  25. Number of Participants Who Developed Positive Titer (≥160) of Binding or Neutralizing Antibodies to rHuPH20

    Number of participants who developed positive titer (rHuPH20 titer ≥160) of binding antibodies to rHuPH20 was reported. Neutralizing antibodies were only tested if the participant had a titer of ≥160 of binding antibodies. Participants with multiple assessments of titer of ≥160 of binding antibodies are counted only once.

    Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)

  26. Percentage of Participants Who Developed Positive Titer (≥160) of Binding or Neutralizing Antibodies to rHuPH20

    Percentage of participants who developed positive titer (rHuPH20 titer ≥160) of binding antibodies to rHuPH20 was reported. Neutralizing antibodies were only tested if the participant had a titer of ≥160 of binding antibodies. Participants with multiple assessments of titer of ≥160 of binding antibodies are counted only once. Percentages are rounded off to whole number at the nearest decimal.

    Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)

  27. Epoch 2: Number of Infusions Per Month

    Time frame: Study Epoch 2: Up to 36 months

  28. Epoch 2: Number of Infusion Sites (Needle Sticks) Per Infusion

    Time frame: Study Epoch 2: Up to 36 months

  29. Epoch 2: Number of Infusion Sites (Needle Sticks) Per Month

    Time frame: Study Epoch 2: Up to 36 months

  30. Epoch 2: Duration of Infusion

    Duration of infusion is calculated as (stop time of infusion - start time of infusion) (in Epoch 2). Duration of infusion is the time from the start of rHuPH20 infusion until the stop time of immunoglobulin infusion.

    Time frame: Study Epoch 2: Up to 36 months

  31. Epoch 2: Maximum Infusion Rate Per Site

    HYQVIA treatment infusions in Epoch 2 were given at a rate of 10 milliliters per hour per site (mL/h/site) to 160 ml/h/site (body weight \[BW\] of \<40 kg) and 10 mL/h/site to 300 mL/h/site (BW of ≥40 kg).

    Time frame: Study Epoch 2: Up to 36 months

  32. Epoch 2: Infusion Volume Per Site

    Infusion volume per site is calculated as (actual IgG volume (mL) / total number of infusion sites used).

    Time frame: Study Epoch 2: Up to 36 months

  33. Epoch 2: Infusions Which Were Discontinued, Slowed, or Interrupted Due to an AE

    Time frame: Study Epoch 2: Up to 36 months

  34. Epoch 2: Percentage of Infusions Which Were Discontinued, Slowed, or Interrupted Due to an AE

    Percentages are rounded off to whole number at the nearest decimal.

    Time frame: Study Epoch 2: Up to 36 months

  35. Epoch 1: Number of Weeks to Reach Final Dose Interval

    Time frame: Epoch 1 (up to 6 weeks)

  36. Epoch 2: Percentage of Participants Who Achieved a Treatment Interval of Three or Four Weeks in Epoch 2

    Percentages are rounded off to whole number at the nearest decimal. Percentages may sum up to more than 100% as assigned treatment interval could be changed during the study.

    Time frame: Study Epoch 2: Up to 36 months

  37. Epoch 2: Percentage of Participants Who Maintained a Treatment Interval of Three or Four Weeks in Epoch 2 for 12 Months

    Percentages are rounded off to whole number at the nearest decimal.

    Time frame: Study Epoch 2: Up to 12 months

  38. Health-related Quality of Life (HRQoL): Change From Baseline in Pediatric Quality of Life Inventory (Peds-QL) Score

    Peds-QL=generic questionnaire developed and validated to measure HRQoL among pediatric population. It included assessment of 4 dimensions: physical functioning (8 items), emotional functioning (8 items), social functioning (8 items), and school functioning (Age groups: Toddler (2-4years),Young child (5-7years),Child (8-12years), and Teens (13-\<16years). Depending on the participants age, questionnaire may be completed by participant or parent/caregiver as appropriate. Items were scored on a 5-point Likert scale: 0=never a problem; 1=almost never a problem; 2=sometimes a problem; 3=often a problem; and 4=almost always a problem). All Scores were transformed on a total scale from 0-100 where, 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicating better health status. End of Epoch 2 summarizes all participant's data for their last epoch 2 visit (so not including the participant that discontinued in epoch 1).

    Time frame: Epoch 1: Baseline (First Infusion); Study Epoch 2: Up to Month 36

  39. HRQoL: Change From Baseline in EuroQol Five Dimensions Questionnaire (EQ-5D) Score

    The EQ-5D is a validated, self-administered assessment of overall health consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Participants were asked to describe their health state that day by choosing 1 of 3 responses that reflect the levels of severity for each of the five dimensions: no problems, some or moderate problems, or extreme problems. The domain scores are calculated with higher scores indicating worsening health status. The EQ-5D also includes a standard vertical 20-cm visual analogue scale (similar to a thermometer) for recording a participant's rating of their current HRQoL state, which ranged from 0 to 100, where 0 indicated worst imaginable health state and 100 was best imaginable health state. End of Epoch 2 summarizes all participant's data for their last epoch 2 visit (so not including the participant that discontinued in epoch 1).

    Time frame: Epoch 1: Baseline (First Infusion); Study Epoch 2: Up to Month 36

  40. Treatment Preference and Satisfaction: Change From Baseline in Assessment of Life Quality Index (LQI) Score

    The LQI is a validated questionnaire assessing participant perceptions of their HRQoL and their treatment specifically among participants who use IgG therapy. This questionnaire covers 4 domains: treatment interferences, therapy-related problems, therapy setting, and treatment costs. The LQI domains are scored from 0 to 100, with higher scores associated with better IgG treatment satisfaction. End of Epoch 2 summarizes all participant's data for their last epoch 2 visit (so not including the participant that discontinued in epoch 1).

    Time frame: Epoch 1: Baseline (First Infusion); Study Epoch 2: Up to Month 36

  41. Treatment Preference and Satisfaction: Change From Baseline in Assessment of Treatment Satisfaction and Medication Questionnaire (TSQM-9) Score

    The TSQM-9 is a 9-item, validated, self-administered instrument to assess participant satisfaction with medication, which assesses 3 domains: effectiveness, convenience, and global satisfaction. The TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction. End of Epoch 2 summarizes all participant's data for their last epoch 2 visit (so not including the participant that discontinued in epoch 1).

    Time frame: Epoch 1: Baseline (First Infusion); Study Epoch 2: Up to Month 36

  42. Treatment Preference and Satisfaction: Number of Participants Who Completed Treatment Preference Questionnaire

    The treatment preference questionnaire, internally developed by the study sponsor, is a self-administered, non-validated scale assessing participant preference for various attributes of immunoglobulin G (IgG) therapy.End of Epoch 2 summarizes all participant's data for their last epoch 2 visit (so not including the participant that discontinued in epoch 1).

    Time frame: Study Epoch 2: Up to Month 36

  43. Health Resource Utilization: Days Not Able to go to School or Work, or to Perform Normal Daily Activities

    Days not able to go to school or work, or to perform normal daily activities due to infection or other illnesses were calculated as days not able to go to school or work, or to perform normal daily activities due to infection or other illnesses per participant-year. Per participant-years = number or days reported / total number of years of study duration, i.e., the sum of study duration for all participants in the analysis set, divided by 365.25.

    Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)

  44. Health Resource Utilization: Days on Antibiotics

    Days on antibiotics were calculated as days on antibiotics per participant-year. Per participant-years = number or days reported / total number of years of study duration, i.e., the sum of study duration for all participants in the analysis set, divided by 365.25.

    Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)

  45. Health Resource Utilization: Number of Hospitalizations

    Number of hospitalizations, indication for the hospitalization (infection or non-infection) were calculated as number of hospitalizations, indication for the hospitalization (infection or non-infection) per participant-year. Per participant-years = number or days reported / total number of years of study duration, i.e., the sum of study duration for all participants in the analysis set, divided by 365.25.

    Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)

  46. Health Resource Utilization: Number of Days Hospitalized Per Participant-Year

    Number of days hospitalized were calculated as number of days hospitalized per participant-year. Per participant-years = number or days reported / total number of years of study duration, i.e., the sum of study duration for all participants in the analysis set, divided by 365.25.

    Time frame: From first dose of study drug up to EOS (up to 4 years 9 months)

07

Results

Posted Oct 23, 2023

Participant flow

Participants took part in the study at 19 investigative sites in the United States from 25 September 2017 to 20 July 2022. Pediatric participants with a diagnosis of primary immunodeficiency diseases (PIDD) were enrolled in this study.

Epoch 1 (Six-week Ramp-up Period)
Participant flow — Epoch 1 (Six-week Ramp-up Period)
MilestoneEpoch 1Epoch 2
Started440
Completed430
Not completed10
Withdrew: Adverse event10
Epoch 2 (36 Months After Epoch 1)
Participant flow — Epoch 2 (36 Months After Epoch 1)
MilestoneEpoch 1Epoch 2
Started043
Completed034
Not completed09
Withdrew: Adverse event01
Withdrew: Physician decision01
Withdrew: Withdrawal by subject06
Withdrew: Reason not specified01

Outcome measures

PrimaryRate Represented as Mean Number of Acute Serious Bacterial Infections (ASBI) Per Participant-year

The rate of ASBI was defined as the mean number of ASBI per participant-year based on the United States (U.S.) Food and drugs Administration (FDA) guidance for industry to support marketing of human immune globulin intravenous (IGIV) as replacement therapy for primary humoral immunodeficiency and the European Medicines Agency (EMA) guideline on the clinical investigation of human normal immunoglobulin for SC and /or intramuscular administration. ASBI included bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess, diagnosed according to the Diagnostic Criteria for Acute Serious Bacterial Infections.

Time frame:
From first dose of study drug up to end of Study Epoch 2 (up to approximately 37.2 months)
Reported as:
Mean · ASBI per participant-year
Rate Represented as Mean Number of Acute Serious Bacterial Infections (ASBI) Per Participant-year
ASBI per participant-yearEpoch 1 + Epoch 2
Rate Represented as Mean Number of Acute Serious Bacterial Infections (ASBI) Per Participant-year0.04 ± 0.027
SecondaryRate Represented as Mean Number of All Infections Per Participant-year

The rate of all infections was defined as the mean number of all infections per participant-year. Number of all infections was calculated as number of infections per participant-year.

Time frame:
From first dose of study drug up to end of Study Epoch 2 (up to approximately 37.2 months)
Reported as:
Mean · infections per participant-year
Rate Represented as Mean Number of All Infections Per Participant-year
infections per participant-yearEpoch 1 + Epoch 2
Rate Represented as Mean Number of All Infections Per Participant-year3.12 ± 0.450
SecondaryEpoch 2: Trough Levels of Immunoglobulin G (IgG) Total and IgG Subclasses
Time frame:
Study Epoch 2, Year 1: Months 0, 6, and 12; Year 2: Months 18, 24 and 36
Reported as:
Mean · grams per liter (g/L)
Epoch 2: Trough Levels of Immunoglobulin G (IgG) Total and IgG Subclasses
grams per liter (g/L)Epoch 2
IgG Total: Month 010.381 ± 2.9191
IgG Total: Month 69.199 ± 1.9577
IgG Total: Month 129.214 ± 1.9800
IgG Total: Month 1813.80 ± NA
IgG Total: Month 2410.80 ± NA
IgG Total: Month 3613.50 ± NA
IgG Subclass 1: Month 05.888 ± 2.7193
IgG Subclass 1: Month 65.317 ± 1.4887
IgG Subclass 1: Month 125.284 ± 1.2103
IgG Subclass 1: Month 187.590 ± NA
IgG Subclass 1: Month 247.710 ± NA
IgG Subclass 2: Month 03.311 ± 0.6833
IgG Subclass 2: Month 63.156 ± 0.6694
IgG Subclass 2: Month 123.106 ± 0.5839
IgG Subclass 2: Month 183.480 ± NA
IgG Subclass 2: Month 243.510 ± NA
IgG Subclass 3: Month 00.534 ± 0.2838
IgG Subclass 3: Month 60.508 ± 0.2545
IgG Subclass 3: Month 120.507 ± 0.2799
IgG Subclass 3: Month 180.360 ± NA
IgG Subclass 3: Month 240.430 ± NA
IgG Subclass 4: Month 00.2998 ± 0.26802
IgG Subclass 4: Month 60.3161 ± 0.32899
IgG Subclass 4: Month 120.3118 ± 0.32790
IgG Subclass 4: Month 180.9380 ± NA
IgG Subclass 4: Month 241.4560 ± NA
SecondaryEpoch 2: Trough Levels of Specific Antibodies to Clinically Relevant Pathogens Categorized as Clostridium Tetani Toxoid and Hepatitis B Virus
Time frame:
Study Epoch 2, Year 2: Months 6, 24, and 36
Reported as:
Mean · international unit per milliliter(IU/mL)
Epoch 2: Trough Levels of Specific Antibodies to Clinically Relevant Pathogens Categorized as Clostridium Tetani Toxoid and Hepatitis B Virus
international unit per milliliter(IU/mL)Epoch 2
Clostridium Tetani Toxoid Antibody: Month 61.685 ± 0.6793
Clostridium Tetani Toxoid Antibody: Month 242.450 ± NA
Clostridium Tetani Toxoid Antibody: Completion/ Termination (Month 36)1.598 ± 0.5889
Hepatitis B Virus Antibody: Month 6199.6 ± 122.97
Hepatitis B Virus Antibody: Month 24146.0 ± NA
Hepatitis B Virus Antibody: Completion/ Termination (Month 36)256.7 ± 219.53
SecondaryEpoch 2: Trough Levels of Specific Antibodies to Clinically Relevant Pathogen Haemophilus Influenzae B
Time frame:
Study Epoch 2, Year 2: Months 6, 24, and 36
Reported as:
Mean · milligrams per liter (mg/L)
Epoch 2: Trough Levels of Specific Antibodies to Clinically Relevant Pathogen Haemophilus Influenzae B
milligrams per liter (mg/L)Epoch 2
Month 61.839 ± 1.5222
Month 241.810 ± NA
Completion/Termination (Month 36)1.678 ± 0.8009
SecondaryEpoch 2: Area Under the Curve Normalized for Week (AUCweek)
Time frame:
Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion
Reported as:
Geometric mean · grams*day per liter (g*day/L)
Epoch 2: Area Under the Curve Normalized for Week (AUCweek)
grams*day per liter (g*day/L)Epoch 2
Epoch 2: Area Under the Curve Normalized for Week (AUCweek)74.57 ± 19.4
SecondaryEpoch 2: Area Under the Curve Over the Infusion Interval (AUCTau)
Time frame:
Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion
Reported as:
Geometric mean · g*day/L
Epoch 2: Area Under the Curve Over the Infusion Interval (AUCTau)
g*day/LEpoch 2
Epoch 2: Area Under the Curve Over the Infusion Interval (AUCTau)288.8 ± 21.7
SecondaryEpoch 2: Apparent Clearance (CL/F)
Time frame:
Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion
Reported as:
Geometric mean · milliliters per day (mL/day)
Epoch 2: Apparent Clearance (CL/F)
milliliters per day (mL/day)Epoch 2
Epoch 2: Apparent Clearance (CL/F)56.45 ± 61.4
SecondaryEpoch 2: Maximum Concentration (Cmax)
Time frame:
Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion
Reported as:
Geometric mean · g/L
Epoch 2: Maximum Concentration (Cmax)
g/LEpoch 2
Epoch 2: Maximum Concentration (Cmax)12.94 ± 17.4
SecondaryEpoch 2: Minimum Concentration (Cmin)
Time frame:
Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion
Reported as:
Geometric mean · g/L
Epoch 2: Minimum Concentration (Cmin)
g/LEpoch 2
Epoch 2: Minimum Concentration (Cmin)8.571 ± 25.6
SecondaryEpoch 2: Time to Maximum Concentration (Tmax)
Time frame:
Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion
Reported as:
Median · days
Epoch 2: Time to Maximum Concentration (Tmax)
daysEpoch 2
Epoch 2: Time to Maximum Concentration (Tmax)4.20 (0.0 to 26.9)
SecondaryEpoch 2: Terminal Half-life (T 1/2)
Time frame:
Study Epoch 2, Month 6: Day 0 pre-infusion, and at Days 2, 4, 10, 21 and 28 post-infusion
Reported as:
Geometric mean · days
Epoch 2: Terminal Half-life (T 1/2)
daysEpoch 2
Epoch 2: Terminal Half-life (T 1/2)44.98 ± 45.9
SecondaryNumber of Participants With Serious Adverse Events (SAEs) Excluding Infections, Related and Not Related

An SAE is defined as an untoward medical occurrence that at any dose is fatal, life-threatening, requires inpatient hospitalization or results in prolongation of an existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event. Number of participants who experienced SAEs, related or not related, was reported.

Time frame:
From first dose of study drug up to EOS (up to 4 years 9 months)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) Excluding Infections, Related and Not Related
ParticipantsEpoch 1Epoch 2
SAE: Related00
SAE: Not Related01
SecondaryRate of SAEs Excluding Infections, Related and Not Related, Per Infusion

Rate of SAEs per infusion was calculated as number of serious adverse events/total number of infusions administered to participants in the analysis set. Rate of SAEs per infusion (excluding infections) was reported.

Time frame:
From first dose of study drug up to EOS (up to 4 years 9 months)
Reported as:
Number · SAEs per infusion
Rate of SAEs Excluding Infections, Related and Not Related, Per Infusion
SAEs per infusionEpoch 1Epoch 2
SAE: Related0.00.0
SAE: Not Related0.00.002
SecondaryNumber of Participants With All Treatment Emergent Adverse Events (TEAEs) Excluding Infections, Related and Not Related

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants who experienced TEAEs, related or not related, was reported.

Time frame:
From first dose of study drug up to EOS (up to 4 years 9 months)
Reported as:
Count of participants · Participants
Number of Participants With All Treatment Emergent Adverse Events (TEAEs) Excluding Infections, Related and Not Related
ParticipantsEpoch 1Epoch 2
TEAE: Related2531
TEAE: Not Related1636
SecondaryRate of All TEAEs Excluding Infections, Related and Not Related, Per Infusion

Rate of all TEAEs per infusion was calculated as number of any adverse reaction events/total number of infusions administered to participants in the analysis set. Rate of any adverse reactions per infusion (excluding infections) was reported.

Time frame:
From first dose of study drug up to EOS (up to 4 years 9 months)
Reported as:
Number · adverse reaction event per infusion
Rate of All TEAEs Excluding Infections, Related and Not Related, Per Infusion
adverse reaction event per infusionEpoch 1Epoch 2
TEAE: Related0.6750.397
TEAE: Not Related0.2700.262
SecondaryNumber of Participants With Local TEAEs Excluding Infections, Related and Not Related

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants who experienced local TEAEs, related or not related, was reported.

Time frame:
From first dose of study drug up to EOS (up to 4 years 9 months)
Reported as:
Count of participants · Participants
Number of Participants With Local TEAEs Excluding Infections, Related and Not Related
ParticipantsEpoch 1Epoch 2
Local TEAE: Related2228
Local TEAE: Not Related26
SecondaryRate of Local TEAEs Excluding Infections, Related and Not Related, Per Infusion

Rate of local TEAEs per infusion was calculated as number of local TEAEs/total number of infusions administered to participants in the analysis set. Rate of local TEAEs per infusion (excluding infections) was reported.

Time frame:
From first dose of study drug up to EOS (up to 4 years 9 months)
Reported as:
Number · local TEAEs per infusion
Rate of Local TEAEs Excluding Infections, Related and Not Related, Per Infusion
local TEAEs per infusionEpoch 1Epoch 2
Local TEAE: Related0.4600.212
Local TEAE: Not Related0.0160.013
SecondaryNumber of Participants With Systemic TEAEs Excluding Infections, Related and Not Related

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants who experienced systemic TEAEs, related or not related, was reported.

Time frame:
From first dose of study drug up to EOS (up to 4 years 9 months)
Reported as:
Count of participants · Participants
Number of Participants With Systemic TEAEs Excluding Infections, Related and Not Related
ParticipantsEpoch 1Epoch 2
Systemic TEAE: Related1220
Systemic TEAE: Not Related1633
SecondaryRate of Systemic TEAEs Excluding Infections, Related and Not Related, Per Infusion

Rate of systemic TEAEs per infusion was calculated as number of systemic TEAEs/total number of infusions administered to participants in the analysis set. Rate of systemic TEAEs per infusion (excluding infections) was reported.

Time frame:
From first dose of study drug up to EOS (up to 4 years 9 months)
Reported as:
Number · systemic TEAEs per infusion
Rate of Systemic TEAEs Excluding Infections, Related and Not Related, Per Infusion
systemic TEAEs per infusionEpoch 1Epoch 2
Systemic TEAE: Related0.2140.185
Systemic TEAE: Not Related0.2540.250
SecondaryNumber of Participants With All Temporally Associated TEAEs Excluding Infections

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants who experienced all temporally associated TEAEs, related or not related, was reported.

Time frame:
From beginning of infusion up to 72 hours post infusion
Reported as:
Count of participants · Participants
Number of Participants With All Temporally Associated TEAEs Excluding Infections
ParticipantsEpoch 1Epoch 2
Number of Participants With All Temporally Associated TEAEs Excluding Infections2735
SecondaryRate of All Temporally Associated TEAEs Excluding Infections Per Infusion

Rate of all temporally associated TEAEs per infusion was calculated as number of all temporally associated TEAEs/total number of infusions administered to participants in the analysis set. Rate of all temporally associated TEAEs per infusion (excluding infections) was reported.

Time frame:
From beginning of infusion up to 72 hours post infusion
Reported as:
Number · temporally associated TEAEs per infusion
Rate of All Temporally Associated TEAEs Excluding Infections Per Infusion
temporally associated TEAEs per infusionEpoch 1Epoch 2
Rate of All Temporally Associated TEAEs Excluding Infections Per Infusion0.7220.460
SecondaryNumber of Participants With All Related (Causally) and/or Temporally Associated TEAEs Excluding Infections

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Number of participants with any related (causally) and/or temporally associated TEAEs (excluding infections) was reported. Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion.

Time frame:
From beginning of infusion up to 72 hours post infusion
Reported as:
Count of participants · Participants
Number of Participants With All Related (Causally) and/or Temporally Associated TEAEs Excluding Infections
ParticipantsEpoch 1Epoch 2
Number of Participants With All Related (Causally) and/or Temporally Associated TEAEs Excluding Infections2735
SecondaryRate of Participants With All Related (Causally) and/or Temporally Associated TEAEs Excluding Infections Per Infusion

Rate of any related (causally) and/or temporally associated TEAEs per infusion was calculated as number of related and/or temporally associated adverse events/ total number of infusions administered to participants in the analysis set. TEAEs recorded in the study database as "possibly related" or "probably related" to HYQVIA are considered HYQVIA-related adverse events. Temporally-associated TEAEs were defined as TEAEs which begin during infusion of IP or within 72 hours following the end of IP infusion. Rate of any related (causally) and/or temporally associated TEAEs per infusion (excluding infections) was reported.

Time frame:
From beginning of infusion up to 72 hours post infusion
Reported as:
Number · related temporally TEAEs per infusion
Rate of Participants With All Related (Causally) and/or Temporally Associated TEAEs Excluding Infections Per Infusion
related temporally TEAEs per infusionEpoch 1Epoch 2
Rate of Participants With All Related (Causally) and/or Temporally Associated TEAEs Excluding Infections Per Infusion0.7620.482
SecondaryPercentage of Participants With Any TEAEs Excluding Infections

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug. Percentages are rounded off to whole number at the nearest decimal.

Time frame:
From first dose of study drug up to EOS (up to 4 years 9 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Any TEAEs Excluding Infections
percentage of participantsEpoch 1Epoch 2
Percentage of Participants With Any TEAEs Excluding Infections65.993.0
SecondaryNumber of Participants Who Developed Positive Titer (≥160) of Binding or Neutralizing Antibodies to rHuPH20

Number of participants who developed positive titer (rHuPH20 titer ≥160) of binding antibodies to rHuPH20 was reported. Neutralizing antibodies were only tested if the participant had a titer of ≥160 of binding antibodies. Participants with multiple assessments of titer of ≥160 of binding antibodies are counted only once.

Time frame:
From first dose of study drug up to EOS (up to 4 years 9 months)
Reported as:
Count of participants · Participants
Number of Participants Who Developed Positive Titer (≥160) of Binding or Neutralizing Antibodies to rHuPH20
ParticipantsEpoch 1 + Epoch 2
Number of Participants Who Developed Positive Titer (≥160) of Binding or Neutralizing Antibodies to rHuPH201
SecondaryPercentage of Participants Who Developed Positive Titer (≥160) of Binding or Neutralizing Antibodies to rHuPH20

Percentage of participants who developed positive titer (rHuPH20 titer ≥160) of binding antibodies to rHuPH20 was reported. Neutralizing antibodies were only tested if the participant had a titer of ≥160 of binding antibodies. Participants with multiple assessments of titer of ≥160 of binding antibodies are counted only once. Percentages are rounded off to whole number at the nearest decimal.

Time frame:
From first dose of study drug up to EOS (up to 4 years 9 months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Developed Positive Titer (≥160) of Binding or Neutralizing Antibodies to rHuPH20
percentage of participantsEpoch 1 + Epoch 2
Percentage of Participants Who Developed Positive Titer (≥160) of Binding or Neutralizing Antibodies to rHuPH202.3
SecondaryEpoch 2: Number of Infusions Per Month
Time frame:
Study Epoch 2: Up to 36 months
Reported as:
Median · infusions per month
Epoch 2: Number of Infusions Per Month
infusions per monthEpoch 2
Epoch 2: Number of Infusions Per Month1.10 (1.0 to 1.5)
SecondaryEpoch 2: Number of Infusion Sites (Needle Sticks) Per Infusion
Time frame:
Study Epoch 2: Up to 36 months
Reported as:
Mean · infusion sites per infusion
Epoch 2: Number of Infusion Sites (Needle Sticks) Per Infusion
infusion sites per infusionEpoch 2
Epoch 2: Number of Infusion Sites (Needle Sticks) Per Infusion1.83 ± 0.366
SecondaryEpoch 2: Number of Infusion Sites (Needle Sticks) Per Month
Time frame:
Study Epoch 2: Up to 36 months
Reported as:
Median · infusion sites per month
Epoch 2: Number of Infusion Sites (Needle Sticks) Per Month
infusion sites per monthEpoch 2
Epoch 2: Number of Infusion Sites (Needle Sticks) Per Month2.17 (1.1 to 2.9)
SecondaryEpoch 2: Duration of Infusion

Duration of infusion is calculated as (stop time of infusion - start time of infusion) (in Epoch 2). Duration of infusion is the time from the start of rHuPH20 infusion until the stop time of immunoglobulin infusion.

Time frame:
Study Epoch 2: Up to 36 months
Reported as:
Median · minutes (mins)
Epoch 2: Duration of Infusion
minutes (mins)Epoch 2
Epoch 2: Duration of Infusion85.0 (45 to 215)
SecondaryEpoch 2: Maximum Infusion Rate Per Site

HYQVIA treatment infusions in Epoch 2 were given at a rate of 10 milliliters per hour per site (mL/h/site) to 160 ml/h/site (body weight \[BW\] of \<40 kg) and 10 mL/h/site to 300 mL/h/site (BW of ≥40 kg).

Time frame:
Study Epoch 2: Up to 36 months
Reported as:
Mean · milliliters per hour per site(mL/h/site)
Epoch 2: Maximum Infusion Rate Per Site
milliliters per hour per site(mL/h/site)Epoch 2
Epoch 2: Maximum Infusion Rate Per Site173.5 ± 81.32
SecondaryEpoch 2: Infusion Volume Per Site

Infusion volume per site is calculated as (actual IgG volume (mL) / total number of infusion sites used).

Time frame:
Study Epoch 2: Up to 36 months
Reported as:
Mean · mL/site
Epoch 2: Infusion Volume Per Site
mL/siteEpoch 2
Epoch 2: Infusion Volume Per Site101.3 ± 51.69
SecondaryEpoch 2: Infusions Which Were Discontinued, Slowed, or Interrupted Due to an AE
Time frame:
Study Epoch 2: Up to 36 months
Reported as:
Number · infusions
Epoch 2: Infusions Which Were Discontinued, Slowed, or Interrupted Due to an AE
infusionsEpoch 2
Infusions That Were Discontinued0
Infusions That Were Slowed0
Infusions That Were Interrupted17
SecondaryEpoch 2: Percentage of Infusions Which Were Discontinued, Slowed, or Interrupted Due to an AE

Percentages are rounded off to whole number at the nearest decimal.

Time frame:
Study Epoch 2: Up to 36 months
Reported as:
Number · percentage of infusions
Epoch 2: Percentage of Infusions Which Were Discontinued, Slowed, or Interrupted Due to an AE
percentage of infusionsEpoch 2
Infusions That Were Discontinued0
Infusions That Were Slowed0
Infusions That Were Interrupted2.69
SecondaryEpoch 1: Number of Weeks to Reach Final Dose Interval
Time frame:
Epoch 1 (up to 6 weeks)
Reported as:
Median · weeks
Epoch 1: Number of Weeks to Reach Final Dose Interval
weeksEpoch 1
Epoch 1: Number of Weeks to Reach Final Dose Interval6.14 (3.0 to 6.6)
SecondaryEpoch 2: Percentage of Participants Who Achieved a Treatment Interval of Three or Four Weeks in Epoch 2

Percentages are rounded off to whole number at the nearest decimal. Percentages may sum up to more than 100% as assigned treatment interval could be changed during the study.

Time frame:
Study Epoch 2: Up to 36 months
Reported as:
Number · percentage of participants
Epoch 2: Percentage of Participants Who Achieved a Treatment Interval of Three or Four Weeks in Epoch 2
percentage of participantsEpoch 2
Every 3 Weeks18.6
Every 4 Weeks83.7
SecondaryEpoch 2: Percentage of Participants Who Maintained a Treatment Interval of Three or Four Weeks in Epoch 2 for 12 Months

Percentages are rounded off to whole number at the nearest decimal.

Time frame:
Study Epoch 2: Up to 12 months
Reported as:
Number · percentage of participants
Epoch 2: Percentage of Participants Who Maintained a Treatment Interval of Three or Four Weeks in Epoch 2 for 12 Months
percentage of participantsEpoch 2
Epoch 2: Percentage of Participants Who Maintained a Treatment Interval of Three or Four Weeks in Epoch 2 for 12 Months74.4
SecondaryHealth-related Quality of Life (HRQoL): Change From Baseline in Pediatric Quality of Life Inventory (Peds-QL) Score

Peds-QL=generic questionnaire developed and validated to measure HRQoL among pediatric population. It included assessment of 4 dimensions: physical functioning (8 items), emotional functioning (8 items), social functioning (8 items), and school functioning (Age groups: Toddler (2-4years),Young child (5-7years),Child (8-12years), and Teens (13-\<16years). Depending on the participants age, questionnaire may be completed by participant or parent/caregiver as appropriate. Items were scored on a 5-point Likert scale: 0=never a problem; 1=almost never a problem; 2=sometimes a problem; 3=often a problem; and 4=almost always a problem). All Scores were transformed on a total scale from 0-100 where, 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicating better health status. End of Epoch 2 summarizes all participant's data for their last epoch 2 visit (so not including the participant that discontinued in epoch 1).

Time frame:
Epoch 1: Baseline (First Infusion); Study Epoch 2: Up to Month 36
Reported as:
Mean · score on a scale
Health-related Quality of Life (HRQoL): Change From Baseline in Pediatric Quality of Life Inventory (Peds-QL) Score
score on a scaleEpoch 1 + Epoch 2
Baseline: 2-4 years72.67 ± 12.969
Baseline: 5-7 years77.29 ± 18.908
Baseline: 8-12 years75.42 ± 17.227
Baseline: 13-<16 years76.09 ± 7.894
Change From Baseline at Epoch 2 Month 12: 2-4 years4.57 ± 17.134
Change From Baseline at Epoch 2 Month 12: 5-7 years-3.74 ± 15.170
Change From Baseline at Epoch 2 Month 12: 8-12 years0.84 ± 21.050
Change From Baseline at Epoch 2 Month 12: 13-<16 years-6.09 ± 8.750
Change From Baseline at Completion/ termination (Month 36): 2-4 years8.73 ± 18.799
Change From Baseline at Completion/ termination (Month 36): 5-7 years-26.09 ± NA
Change From Baseline at Completion/ termination (Month 36): 8-12 years-5.16 ± 19.735
Change From Baseline at Completion/ termination (Month 36): 13-<16 years3.62 ± 5.471
Change From Baseline at End of Epoch 2: 2-4 years8.16 ± 17.730
Change From Baseline at End of Epoch 2: 5-7 years-4.59 ± 16.266
Change From Baseline at End of Epoch 2: 8-12 years-1.98 ± 14.027
Change From Baseline at End of Epoch 2: 13-<16 years-2.45 ± 8.807
SecondaryHRQoL: Change From Baseline in EuroQol Five Dimensions Questionnaire (EQ-5D) Score

The EQ-5D is a validated, self-administered assessment of overall health consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Participants were asked to describe their health state that day by choosing 1 of 3 responses that reflect the levels of severity for each of the five dimensions: no problems, some or moderate problems, or extreme problems. The domain scores are calculated with higher scores indicating worsening health status. The EQ-5D also includes a standard vertical 20-cm visual analogue scale (similar to a thermometer) for recording a participant's rating of their current HRQoL state, which ranged from 0 to 100, where 0 indicated worst imaginable health state and 100 was best imaginable health state. End of Epoch 2 summarizes all participant's data for their last epoch 2 visit (so not including the participant that discontinued in epoch 1).

Time frame:
Epoch 1: Baseline (First Infusion); Study Epoch 2: Up to Month 36
Reported as:
Mean · score on a scale
HRQoL: Change From Baseline in EuroQol Five Dimensions Questionnaire (EQ-5D) Score
score on a scaleEpoch 1 + Epoch 2
Baseline: Visual Analogue Scale (VAS) Score82.84 ± 16.806
Baseline: Mobility1.07 ± 0.258
Baseline: Self-care1.16 ± 0.485
Baseline: Usual Activities1.14 ± 0.413
Baseline: Pain/ Discomfort1.28 ± 0.454
Baseline: Anxiety/ Depression1.28 ± 0.549
Change From Baseline at Epoch 2 Month 12: VAS Score0.64 ± 23.504
Change From Baseline at Epoch 2 Month 12: Mobility-0.09 ± 0.292
Change From Baseline at Epoch 2 Month 12: Self-care-0.12 ± 0.415
Change From Baseline at Epoch 2 Month 12: Usual Activities0.03 ± 0.394
Change From Baseline at Epoch 2 Month 12: Pain/ Discomfort0.18 ± 0.528
Change From Baseline at Epoch 2 Month 12: Anxiety/ Depression-0.06 ± 0.556
Change From Baseline at Completion/ Termination (Month 36): VAS Score-8.93 ± 26.993
Change From Baseline at Completion/ Termination (Month 36): Mobility0.00 ± 0.000
Change From Baseline at Completion/ Termination (Month 36): Self-care0.00 ± 0.000
Change From Baseline at Completion/ Termination (Month 36): Usual Activities0.00 ± 0.535
Change From Baseline at Completion/ Termination (Month 36): Pain/ Discomfort-0.07 ± 0.594
Change From Baseline at Completion/ Termination (Month 36): Anxiety/ Depression-0.27 ± 0.594
Change From Baseline at End of Epoch 2: VAS Score-2.83 ± 24.895
Change From Baseline at End of Epoch 2: Mobility-0.07 ± 0.264
Change From Baseline at End of Epoch 2: Self-care-0.10 ± 0.374
Change From Baseline at End of Epoch 2: Usual Activities0.00 ± 0.387
Change From Baseline at End of Epoch 2: Pain/ Discomfort0.07 ± 0.565
Change From Baseline at End of Epoch 2: Anxiety/ Depression-0.10 ± 0.539
SecondaryTreatment Preference and Satisfaction: Change From Baseline in Assessment of Life Quality Index (LQI) Score

The LQI is a validated questionnaire assessing participant perceptions of their HRQoL and their treatment specifically among participants who use IgG therapy. This questionnaire covers 4 domains: treatment interferences, therapy-related problems, therapy setting, and treatment costs. The LQI domains are scored from 0 to 100, with higher scores associated with better IgG treatment satisfaction. End of Epoch 2 summarizes all participant's data for their last epoch 2 visit (so not including the participant that discontinued in epoch 1).

Time frame:
Epoch 1: Baseline (First Infusion); Study Epoch 2: Up to Month 36
Reported as:
Mean · score on a scale
Treatment Preference and Satisfaction: Change From Baseline in Assessment of Life Quality Index (LQI) Score
score on a scaleEpoch 1 + Epoch 2
Baseline: Treatment Interferences69.77 ± 17.518
Baseline: Therapy-related Problems65.21 ± 17.080
Baseline: Therapy Setting85.66 ± 14.610
Baseline: Treatment Costs60.85 ± 27.310
Change From Baseline at Epoch 2 Month 12: Treatment Interferences4.71 ± 18.419
Change From Baseline at Epoch 2 Month 12: Therapy-related Problems4.67 ± 17.670
Change From Baseline at Epoch 2 Month 12: Therapy Setting-6.23 ± 23.189
Change From Baseline at Epoch 2 Month 12: Treatment Costs4.55 ± 36.330
Change From Baseline at Completion/Termination (Month 36): Treatment Interferences-10.52 ± 23.850
Change From Baseline at Completion/Termination (Month 36): Therapy-related Problems-13.39 ± 31.656
Change From Baseline at Completion/Termination (Month 36): Therapy Setting-15.87 ± 27.808
Change From Baseline at Completion/Termination (Month 36): Treatment Costs-1.19 ± 32.826
Change From Baseline at End of Epoch 2: Treatment Interferences1.49 ± 20.908
Change From Baseline at End of Epoch 2: Therapy-related Problems0.41 ± 24.399
Change From Baseline at End of Epoch 2: Therapy Setting-10.16 ± 24.718
Change From Baseline at End of Epoch 2: Treatment Costs4.27 ± 35.164
SecondaryTreatment Preference and Satisfaction: Change From Baseline in Assessment of Treatment Satisfaction and Medication Questionnaire (TSQM-9) Score

The TSQM-9 is a 9-item, validated, self-administered instrument to assess participant satisfaction with medication, which assesses 3 domains: effectiveness, convenience, and global satisfaction. The TSQM-9 domain scores range from 0 to 100 with higher scores representing higher satisfaction. End of Epoch 2 summarizes all participant's data for their last epoch 2 visit (so not including the participant that discontinued in epoch 1).

Time frame:
Epoch 1: Baseline (First Infusion); Study Epoch 2: Up to Month 36
Reported as:
Mean · score on a scale
Treatment Preference and Satisfaction: Change From Baseline in Assessment of Treatment Satisfaction and Medication Questionnaire (TSQM-9) Score
score on a scaleEpoch 1 + Epoch 2
Baseline: Effectiveness74.81 ± 15.494
Baseline: Convenience66.15 ± 16.436
Baseline: Global Satisfaction79.07 ± 16.525
Change From Baseline at Epoch 2, Month 12: Effectiveness6.40 ± 16.204
Change From Baseline at Epoch 2, Month 12: Convenience2.19 ± 19.834
Change From Baseline at Epoch 2, Month 12: Global Satisfaction4.76 ± 18.529
Change From Baseline at Completion/ termination (Month 36): Effectiveness-12.70 ± 33.577
Change From Baseline at Completion/ termination (Month 36): Convenience-7.14 ± 20.375
Change From Baseline at Completion/ termination (Month 36): Global Satisfaction-17.35 ± 36.283
Change From Baseline at end of Epoch 2: Effectiveness3.52 ± 20.591
Change From Baseline at end of Epoch 2: Convenience-0.81 ± 20.244
Change From Baseline at end of Epoch 2: Global Satisfaction-0.17 ± 24.406
SecondaryTreatment Preference and Satisfaction: Number of Participants Who Completed Treatment Preference Questionnaire

The treatment preference questionnaire, internally developed by the study sponsor, is a self-administered, non-validated scale assessing participant preference for various attributes of immunoglobulin G (IgG) therapy.End of Epoch 2 summarizes all participant's data for their last epoch 2 visit (so not including the participant that discontinued in epoch 1).

Time frame:
Study Epoch 2: Up to Month 36
Reported as:
Count of participants · Participants
Treatment Preference and Satisfaction: Number of Participants Who Completed Treatment Preference Questionnaire
ParticipantsEpoch 2
Month 1234
Completion/ Termination (Month 36)14
End of Epoch 242
SecondaryHealth Resource Utilization: Days Not Able to go to School or Work, or to Perform Normal Daily Activities

Days not able to go to school or work, or to perform normal daily activities due to infection or other illnesses were calculated as days not able to go to school or work, or to perform normal daily activities due to infection or other illnesses per participant-year. Per participant-years = number or days reported / total number of years of study duration, i.e., the sum of study duration for all participants in the analysis set, divided by 365.25.

Time frame:
From first dose of study drug up to EOS (up to 4 years 9 months)
Reported as:
Number · days per participant-year
Health Resource Utilization: Days Not Able to go to School or Work, or to Perform Normal Daily Activities
days per participant-yearEpoch 1 + Epoch 2
Health Resource Utilization: Days Not Able to go to School or Work, or to Perform Normal Daily Activities4.28
SecondaryHealth Resource Utilization: Days on Antibiotics

Days on antibiotics were calculated as days on antibiotics per participant-year. Per participant-years = number or days reported / total number of years of study duration, i.e., the sum of study duration for all participants in the analysis set, divided by 365.25.

Time frame:
From first dose of study drug up to EOS (up to 4 years 9 months)
Reported as:
Number · days per participant-year
Health Resource Utilization: Days on Antibiotics
days per participant-yearEpoch 1 + Epoch 2
Health Resource Utilization: Days on Antibiotics26.77
SecondaryHealth Resource Utilization: Number of Hospitalizations

Number of hospitalizations, indication for the hospitalization (infection or non-infection) were calculated as number of hospitalizations, indication for the hospitalization (infection or non-infection) per participant-year. Per participant-years = number or days reported / total number of years of study duration, i.e., the sum of study duration for all participants in the analysis set, divided by 365.25.

Time frame:
From first dose of study drug up to EOS (up to 4 years 9 months)
Reported as:
Number · hospitalizations per participant-year
Health Resource Utilization: Number of Hospitalizations
hospitalizations per participant-yearEpoch 1 + Epoch 2
Health Resource Utilization: Number of Hospitalizations0.08
SecondaryHealth Resource Utilization: Number of Days Hospitalized Per Participant-Year

Number of days hospitalized were calculated as number of days hospitalized per participant-year. Per participant-years = number or days reported / total number of years of study duration, i.e., the sum of study duration for all participants in the analysis set, divided by 365.25.

Time frame:
From first dose of study drug up to EOS (up to 4 years 9 months)
Reported as:
Number · days per participant-year
Health Resource Utilization: Number of Days Hospitalized Per Participant-Year
days per participant-yearEpoch 1 + Epoch 2
Health Resource Utilization: Number of Days Hospitalized Per Participant-Year0.21

Adverse events

Collected over From first dose of study drug up to EOS (up to 4 years 9 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Epoch 10/44 (0%)1/44 (2.3%)28/44 (63.6%)
Epoch 20/43 (0%)3/43 (7%)40/43 (93%)
Most frequent serious events
Most frequent serious events
EventEpoch 1Epoch 2
Adenovirus infectionInfections and infestations0/441/43
Clostridium difficile colitisInfections and infestations0/441/43
Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders0/441/43
PneumoniaInfections and infestations1/440/43
Most frequent other events
Showing 10 of 37
Most frequent other events
EventEpoch 1Epoch 2
HeadacheNervous system disorders7/4416/43
SinusitisInfections and infestations4/4416/43
Infusion site painGeneral disorders10/4415/43
PyrexiaGeneral disorders0/4412/43
Infusion site erythemaGeneral disorders5/4410/43
Infusion site extravasationGeneral disorders2/4410/43
Infusion site pruritusGeneral disorders3/4410/43
Infusion site swellingGeneral disorders3/449/43
Upper respiratory tract infectionInfections and infestations1/448/43
Viral upper respiratory tract infectionInfections and infestations2/448/43

Baseline characteristics

Full Analysis Set (FAS) included all participants who provided informed consent, and met enrollment eligibility.

Age, Continuous
Age, Continuous(years)Epoch 1
Mean9.0 ± 3.63
Sex: Female, Male
Sex: Female, Male(Participants)Epoch 1
Female18
Male26
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Epoch 1
Hispanic or Latino5
Not Hispanic or Latino39
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Epoch 1
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White40
More than one race1
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(Participants)Epoch 1
United States44
Height
Height(cm)Epoch 1
Mean133.60 ± 24.024
Weight
Weight(kg)Epoch 1
Mean37.78 ± 19.858
08

Study locations

19 sites
  • University of Alabama Medical Center
    Birmingham, Alabama 35294, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
  • University of Miami Pediatric Allergy and Immunology
    Miami, Florida 33136, United States
  • University of South Florida Physician Group
    Saint Petersburg, Florida 33701, United States
  • Georgia Pollens Clinical Research Centers, Inc.
    Albany, Georgia 31707, United States
  • Emory Healthcare
    Atlanta, Georgia 30322, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • Women & Children's Hospital of Buffalo
    Buffalo, New York 14203, United States
  • Northwell Health, Inc. PRIME
    Great Neck, New York 11021, United States
  • Stony Brook Children's Hospital
    Stony Brook, New York 11794, United States
  • Carolinas Healthcare System
    Charlotte, North Carolina 28203, United States
  • Allergy Asthma & Immunology Relief of Charlotte
    Charlotte, North Carolina 28277, United States
  • OK Institute of Allergy & Asthma Clinical Research, LLC
    Oklahoma City, Oklahoma 73131, United States
  • Vital Prospects Clinical Research Institute, P.C.
    Tulsa, Oklahoma 74136, United States
  • Allergy Partners of North Texas Research
    Dallas, Texas 75230, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • Section on Immunopathogenesis and Clinical Immunology
    Fairfax, Virginia 22030, United States
  • Marshall University Joan C. Edwards School of Medicine
    Charleston, West Virginia 25701, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Jul 2022, 57 months.

Results were first posted in Oct 2023, 1 year 3 months after primary completion.

Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's 57 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2017
First posted
Sep 11, 2017
StartActual
Sep 25, 2017
Primary completionActual
Jul 20, 2022
CompletionActual
Jul 20, 2022
Results first posted
Oct 23, 2023
Last update
Oct 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03277313
Collaborators
Baxalta Innovations GmbH, now part of Shire
Responsible party
Sponsor
First posted
Sep 11, 2017
Start date
Sep 25, 2017
Primary completion
Jul 20, 2022
Completion
Jul 20, 2022
Results posted
Oct 23, 2023
Last update
Oct 23, 2023

Study contacts

Study Director
study director · Shire

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Immunoglobulin G · Hyaluronoglucosaminidase

Start the discussion